2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

• Published in: Journal of the American College of Cardiology Vol. 83; no. 1; pp. 109 - 279
• Main Authors: Joglar, José A, Chung, Mina K, Armbruster, Anastasia L, Benjamin, Emelia J, Chyou, Janice Y, Cronin, Edmond M, Deswal, Anita, Eckhardt, Lee L, Goldberger, Zachary D, Gopinathannair, Rakesh, Gorenek, Bulent, Hess, Paul L, Hlatky, Mark, Hogan, Gail, Ibeh, Chinwe, Indik, Julia H, Kido, Kazuhiko, Kusumoto, Fred, Link, Mark S, Linta, Kathleen T, Marcus, Gregory M, McCarthy, Patrick M, Patel, Nimesh, Patton, Kristen K, Perez, Marco V, Piccini, Jonathan P, Russo, Andrea M, Sanders, Prashanthan, Streur, Megan M, Thomas, Kevin L, Times, Sabrina, Tisdale, James E, Valente, Anne Marie, Van Wagoner, David R
• Format: Journal Article
• Language: English
• Published: United States 02.01.2024
• Subjects: American Heart Association; Atrial Fibrillation - diagnosis; Atrial Fibrillation - epidemiology; Atrial Fibrillation - therapy; Cardiology; Humans; Risk Factors; Thromboembolism; United States - epidemiology; United States; ACC/AHA Clinical Practice Guidelines; coronary artery disease; antiplatelet agents; thromboembolism; atrial flutter; stents; myocardial infarction; exercise; idarucizumab; rivaroxaban; cardioversion; atrial fibrillation; percutaneous coronary intervention; acute coronary syndrome; anticoagulants; dabigatran; sleep apnea; obesity; alcohol; anticoagulation agents; heart failure; left atrial appendage occlusion; risk factors; catheter ablation; apixaban; pulmonary vein isolation; stroke; edoxaban; warfarin; surgical ablation; coronary heart disease; hypertension
• ISSN: 1558-3597; 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2023.08.017

The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" and the "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.